Welcome to our dedicated page for Brain Scientific news (Ticker: BRSF), a resource for investors and traders seeking the latest updates and insights on Brain Scientific stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Brain Scientific's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Brain Scientific's position in the market.
Brain Scientific (OTCQB: BRSF) and JelikaLite have announced a collaboration to launch a clinical trial aimed at reducing autism symptoms in children. The trial, titled 'Transcranial Photobiomodulation for Reducing Autism Symptoms in Children', will involve 30 participants in New York City starting in March 2021. JelikaLite's device, Cognilum, applies photobiomodulation therapy, while Brain Scientific's NeuroEEG will monitor brain activity. This partnership seeks to identify new treatment methods and aims to develop a home-use wearable device for continuous monitoring.
Brain Scientific (OTCQB: BRSF) announced its feature in an audio broadcast via NetworkNewsAudio, boosting visibility and brand awareness in the investment community. The release highlights the FDA 510(k) clearance for its NeuroCap™, an advanced EEG electrode array designed for quick EEG recordings in clinical settings. The NeuroCap™ has been improved with better adhesion and a new extra small size, increasing its application scope. This disposable EEG headset is compatible with most encephalographs and can be applied in just five minutes.
Brain Scientific (BRSF) has received FDA 510(k) clearance for its next-generation NeuroCap™ device, designed for rapid EEGs in clinical settings. The new version features improved adhesion and an expanded size range, targeting broader applications beyond intensive care units and ERs. The NeuroCap™ is a disposable headset with 22 electrodes, compatible with most encephalographs, and can be applied within 5 minutes. With only 30% of U.S. hospitals equipped for routine EEGs, this innovation aims to enhance patient access to neurological care, particularly crucial during the ongoing pandemic.
Brain Scientific (BRSF) has submitted a 510(k) application to the FDA for its NeuroCap™ device, designed for rapid EEGs in resource-limited settings. This hospital-grade disposable headset features 22 electrodes and can be applied in just 5 minutes, reducing the need for disinfection. With neurological symptoms prevalent in over 80% of hospitalized COVID-19 patients, the demand for such devices is increasing. The company estimates a potential market of approximately 5 million patients in US emergency departments and ICUs who could benefit from routine EEG tests.